Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%
Market cap
$681.6M
P/E
62.4×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
5 3 2 6 6 5 — — — —
P/E ratio
441.75 0.00 0.00 60.74 63.00 77.31 80.75 80.75 80.75 80.75
Altman Z-Score
3.88 2.59 2.15 2.34 1.95 3.12 — — — —
P/S ratio
3.24 2.27 3.08 3.65 29.41 44.99 52.19 52.19 52.19 52.19
Altman Z″-Score (non-manufacturers)
2.28 2.26 2.37 2.65 2.33 2.66 (1.44) — — (7.55)
P/FCF ratio
22.56 0.00 0.00 50.50 314.61 79.97 57.90 57.90 57.90 57.90
Beneish M-Score
(2.78) (2.36) (1.94) (2.71) (2.95) (2.98) (2.59) — — —
P/Operating CF
113.67 72.45 65.27 138.41 382.16 489.96 164.75 164.75 164.75 164.75
P/B ratio
4.39 3.06 3.45 3.69 30.09 52.65 66.90 66.90 66.90 66.90
Price to Tangible BV
8.60 4.22 5.12 5.83 53.21 108.09 153.70 153.70 153.70 153.70
EV/Sales
3.02 1.99 2.77 3.29 29.25 44.79 52.01 52.01 52.01 52.01
EV/EBITDA
30.63 79.28 64.58 41.83 188.57 114.81 127.13 127.13 127.13 127.13
EV/Operating CF
20.75 (329.00) (39.33) 25.07 167.87 74.71 57.70 57.70 57.70 57.70
EV/FCF
21.04 (184.03) (34.00) 45.55 312.97 79.60 57.70 57.70 57.70 57.70
Quick Ratio
2.03 3.02 3.33 3.94 4.75 3.15 0.90 1.17 1.13 0.84
Current Ratio
2.59 3.77 4.06 4.65 5.33 3.43 1.05 1.40 1.45 1.21
Net Debt/EBITDA
(2.21) (11.48) (7.12) (2.36) (1.55) (0.64) (0.25) (0.18) 0.96 (3.29)
Debt/Assets
19.61% 20.60% 29.91% 31.33% 35.46% 36.27% 21.90% 33.99% 0.00% 53.16%
Debt/Equity
0.35 0.37 0.63 0.65 0.73 0.83 0.48 1.18 5.10 2.45
Asset Turnover
0.84 0.69 0.55 0.50 0.49 0.63 0.75 0.82 1.62 0.10
Operating CF/Net income
19.19 0.15 1.64 1.64 2.37 2.22 1.84 1.17 (0.40) 0.57
Capex/Depreciation
(0.07) (0.05) (0.09) (0.15) (0.85) (1.84) (4.39) 0.00 0.00 0.00
Interest Coverage
— — — — — — — 0.00 0.00 (3.80)
ROE
1.14% (5.38%) (4.98%) 6.88% 8.50% 25.11% 43.08% 63.57% (380.21%) (76.40%)
ROA
0.63% (2.74%) (2.37%) 3.32% 3.92% 11.20% 16.14% 15.12% (137.67%) (11.06%)
ROIC
8.27% (3.97%) (2.34%) 8.73% 5.98% 36.93% 43.09% 0.00% 0.00% 0.00%
Return on Tangible Assets
1.49% (5.58%) (4.25%) 5.99% 7.41% 19.01% 274.83% 60.60% (213.33%) (104.04%)
Average Days of Receivables
53.08 67.33 68.68 49.03 55.03 61.76 55.58 43.22 41.47 261.82
Research and Development Expense of Revenue
26.68% 27.98% 28.09% 25.55% 35.38% 18.15% 16.78% 20.71% 20.26% 92.81%
Selling, General and Administrative Expense of Revenue
56.08% 63.75% 73.34% 64.11% 48.48% 35.67% 34.80% 32.50% 38.55% 47.74%
Intangible Assets out of Total Assets
0.27 0.15 0.15 0.18 0.21 0.22 0.31 0.24 0.00 0.45
Share Based Compensation of Revenue
3.66% 3.78% 3.77% 3.11% 4.55% 3.08% 2.26% 0.00% 0.00% 0.00%
Graham Net Nets
0.06 0.15 0.10 0.07 0.01 0.00 0.00 0.00 0.00 0.00
Graham Number
1.90 0.00 0.00 3.65 0.97 1.13 0.00 0.00 0.00 0.00
Earnings Yield
0.23% (1.79%) (1.74%) 1.65% 1.59% 1.29% 1.24% 1.24% 1.24% 1.24%
Free Cash Flow Yield
4.43% (0.47%) (2.65%) 1.98% 0.32% 1.25% 1.73% 1.73% 1.73% 1.73%
Revenue per Share
5.46 4.43 3.73 3.17 3.10 3.33 3.02 2.53 0.22 0.04
Operating CF per Share
0.79 (0.03) (0.26) 0.35 0.59 1.31 1.19 0.55 0.07 (0.03)
Capex per Share
(0.01) (0.01) (0.02) (0.03) (0.26) (0.24) (0.41) 0.00 0.00 0.00
Free Cash Flow per Share
0.78 (0.04) (0.29) 0.32 0.33 1.07 0.78 0.55 0.07 (0.03)
Cash per Share
2.61 2.50 3.25 3.20 2.99 3.24 1.19 1.50 0.14 0.08
Shareholders Equity per Share
4.02 3.29 3.33 3.15 3.00 2.88 1.87 1.16 0.04 0.07
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.02 3.29 3.33 3.15 3.00 2.88 1.87 1.16 0.04 0.07
Free Cash Flow
53.95 (2.59) (18.77) 20.48 21.13 68.33 49.04 33.69 36.55 (10.53)
Working Capital
183.68 204.64 238.37 217.80 202.67 186.36 5.17 37.75 33.14 11.38
Capital Expenditures
(0.75) (0.80) (1.46) (1.98) (16.72) (15.30) (25.44) (4.33) (7.28) (1.59)
Net Current Asset Value
76.61 99.52 72.27 56.34 45.05 28.19 (19.07) (42.96) (74.49) (39.08)
EV/EBIT
43.93 0.00 0.00 8.77 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.01 0.01 0.08 0.07 0.13 0.00 0.00 0.00
Price to Operating Income
47.10 0.00 0.00 9.72 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.55 2.07 1.64 1.27 1.48 0.68 0.61 0.47 0.41 0.13
Cash ROIC
9.72% (0.55%) (3.29%) 3.75% 4.02% 12.62% 19.82% 13.63% 19.32% (7.89%)
Accounts Receivable Turnover
6.87 5.89 6.65 7.14 6.04 6.56 8.02 10.13 8.90 1.38
Accounts Payable Turnover
0.53 0.51 0.40 0.36 0.47 0.53 0.99 3.14 2.20 0.66
Inventory Turnover
0.75 0.63 0.51 0.50 0.87 1.26 1.32 1.42 0.93 0.28
Average Days of Payables
849.52 686.83 1,050.00 1,131.97 733.26 739.12 619.53 93.51 217.97 379.29
Days of Inventory on Hand
520.64 574.57 821.73 879.68 471.49 328.06 247.27 243.78 423.78 1,203.98
Average Receivables
54.76 50.49 36.89 28.80 32.94 32.36 23.61 15.33 12.13 12.13
Average Payables
86.26 69.57 63.50 48.47 45.07 44.13 24.12 9.50 8.66 8.66
Average Inventory
60.31 56.24 49.54 34.82 24.23 18.68 18.05 21.00 20.49 20.49
Average Assets
449.97 431.42 444.33 411.56 407.88 337.02 251.11 190.04 66.73 166.84
Average Common Equity
249.08 219.92 211.71 198.78 188.18 150.34 94.11 45.19 24.16 24.16

Fold the line items

Columns are period end dates